Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/28558
Title: MicroRNA manipulation in colorectal cancer cells : from laboratory to clinical application
Authors: Aslam, Muhammad Imran
Patel, Maleene
Singh, Baljit
Jameson, John Stuart
Pringle, James Howard
First Published: 20-Jun-2012
Publisher: BioMed Central Ltd
Citation: Journal of Translational Medicine, 2012, 10 : 128
Abstract: The development of Colorectal Cancer (CRC) follows a sequential progression from adenoma to the carcinoma. Therefore, opportunities exist to interfere with the natural course of disease development and progression. Dysregulation of microRNAs (miRNAs) in cancer cells indirectly results in higher levels of messenger RNA (mRNA) specific to tumour promoter genes or tumour suppressor genes. This narrative review aims to provide a comprehensive review of the literature about the manipulation of oncogenic or tumour suppressor miRNAs in colorectal cancer cells for the purpose of development of anticancer therapies. A literature search identified studies describing manipulation of miRNAs in colorectal cancer cells in vivo and in vitro. Studies were also included to provide an update on the role of miRNAs in CRC development, progression and diagnosis. Strategy based on restoration of silenced miRNAs or inhibition of over expressed miRNAs has opened a new area of research in cancer therapy. In this review article different techniques for miRNA manipulation are reviewed and their utility for colorectal cancer therapy has been discussed in detail. Restoration of normal equilibrium for cancer related miRNAs can result in inhibition of tumour growth, apoptosis, blocking of invasion, angiogenesis and metastasis. Furthermore, drug resistant cancer cells can be turned into drug sensitive cells on alteration of specific miRNAs in cancer cells. MiRNA modulation in cancer cells holds great potential to replace current anticancer therapies. However, further work is needed on tissue specific delivery systems and strategies to avoid side effects.
DOI Link: 10.1186/1479-5876-10-128
eISSN: 1479-5876
Links: http://www.translational-medicine.com/content/10/1/128
http://hdl.handle.net/2381/28558
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2012 Aslam et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
10.1186_1479-5876-10-128.pdfPublished (publisher PDF)3.06 MBUnknownView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.